These 5 Healthcare Penny Stocks Are Poised To Jump

1. Biodel Inc (NASDAQ:BIOD)

Investors with Long Positions (as of June 30): 9

Aggregate Value of Investors’ Holdings (as of June 30): $16.27 Million

The $41.02 million specialty pharmaceutical company gained a significant increase in traction from hedge funds during the second quarter, despite the stock price tumbling by 50% on a year-to-date basis. Three additional hedge funds had long positions in the company and their aggregate investment increased by $13.64 million in the second quarter. At the end of June the concentration of hedge fund investment in Biodel stood at 25.4%. Biodel Inc (NASDAQ:BIOD) is focused on the development of treatments for diabetic patients and its lead candidate is the Glucagon Emergency Management (GEM) program, which comprises lyophilized glucagon and a liquid diluent in a proprietary injection device from Unilife Medical Solutions Incorporated. The product is new in the sense that it simplifies the administration of glucagon, thereby reducing caregiver training requirements, the likelihood of dosing hours, and also the time required to deliver the rescue therapy. In the first quarter the company announced positive data from the Phase 1 trial of the related BIOD-961. Among Biodel Inc (NASDAQ:BIOD)’s top ten stockholders within our database, Hal Mintz‘s Sabby Capital was the most bullish on the company during the June trimester, raising its stake by 429% to 1.15 million shares valued at $1.18 million.

Disclosure: None